Clinical experience in using sorafenib in patients with advanced kidney cancer
| Autor: | A. V. Zyryanov, V. N. Oshchepkov, L. A. Burkhanova |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Sorafenib renal cell carcinoma medicine.medical_specialty Urology medicine.medical_treatment Systemic therapy Targeted therapy Refractory Renal cell carcinoma Internal medicine medicine Radiology Nuclear Medicine and imaging Neoadjuvant therapy business.industry Therapeutic effect Cancer medicine.disease palliative nephrectomy neoadjuvant targeted therapy Nephrology Medicine sorafenib Surgery business medicine.drug |
| Zdroj: | Onkourologiâ, Vol 13, Iss 2, Pp 124-127 (2017) |
| ISSN: | 1996-1812 1726-9776 |
| DOI: | 10.17650/1726-9776-2017-13-2-124-127 |
| Popis: | In the era of targeted therapy, the attention of researchers is focused on the role of neoadjuvant targeted therapy in the treatment of patients with renal cell carcinoma. The advantages of neoadjuvant therapy for advanced renal cell carcinoma include: detection of patients with primary refractory tumors, recurring tumors, simple onset of systemic therapy. One of the most popular and suitable for neoadjuvant targeted therapy is sorafenib. The use of this drug, in our opinion, can significantly improve the results of treatment of such patients. The article describes the description of 3 clinical observations of a widespread cancer of the kidneys treated in a somatic mode in the neoadjuvant mode. Range of therapeutic effects from progressive diseases to stabilization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|